The FDA has accelerated its review of Novartis’ sickle cell drug crizanlizumab after the company filed phase 2 results showing its effectiveness as a treatment for life threatening and pain
UK-based biotech PhoreMost has begun a collaboration with India’s Centre for Chemical Biology (CCBT) and Therapeutics, focused on novel target sights for new drugs.